This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan and Upjohn’s merger plans face New Zealand regulatory review with pricing, quality focus

By Laurel Henning ( January 14, 2020, 05:54 GMT | Insight) -- Plans by US-based pharmaceutical company Mylan to combine with Pfizer’s off-patent drug business Upjohn are under scrutiny in New Zealand after the country’s competition regulator announced today it had started a review of the proposed all-stock deal. The New Zealand Commerce Commission said its review of the international merger would focus on whether the loss of competition between the companies risks a reduction in quality alongside price increases. Plans by US-based pharmaceutical company Mylan to combine with Pfizer's off-patent drug business Upjohn are under scrutiny in New Zealand after the country's competition regulator announced today it had started a review of the proposed all-stock deal. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login